Lung Cancer Clinical Trial
Official title:
Phase I Trial of Escalating Doses of BNP7787 in Patients With Solid Tumors Undergoing Treatment With Cisplatin and Taxol
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Chemoprotective drugs such as dimesna may protect normal cells
from the side effects of chemotherapy.
PURPOSE: This phase I trial is studying the side effects and best dose of dimesna in
treating patients with solid tumors who are receiving cisplatin and paclitaxel.
OBJECTIVES:
- Determine the maximum tolerated dose (MTD) of dimesna administered prior to cisplatin
and paclitaxel in patients with solid tumors.
- Determine the dose related qualitative and quantitative side effects of dimesna
administered on this schedule in these patients.
- Determine the minimum safe volume of intravenous hydration after the determination of
the MTD of dimesna in these patients.
- Investigate the possible protective side effects of dimesna in reducing or preventing
the development of cisplatin induced nephrotoxicity and observe possible protective
effects against cisplatin or paclitaxel related neurotoxicity and myelosuppression in
these patients.
- Investigate the pharmacokinetic behavior of dimesna in the plasma and urine on this
schedule of administration in this patient population.
OUTLINE: This is a dose-escalation, two-stage, multicenter study.
During stage I, patients receive a single dose of dimesna IV over 15 minutes 7 days prior to
chemotherapy. Patients then receive paclitaxel IV over 3 hours followed by dimesna IV over
15-30 minutes followed immediately by cisplatin IV over 1 hour on day 1 every 3 weeks.
Patients continue courses of paclitaxel, dimesna, and cisplatin every 3 weeks in the absence
of disease progression or unacceptable toxicity for up to 6 courses.
In stage I, cohorts of 3-6 patients each receive escalating doses of dimesna until the
maximum tolerated dose (MTD) is reached. The MTD is defined as the highest dose at which no
more than 1 of 6 patients experiences dose limiting toxicity (DLT). The MTD of dimesna is
then used in stage II of the study, in which the volume of pre and post cisplatin
intravenous saline hydration is reduced in cohorts of 3-6 patients each. The MTD intensity
of cisplatin is defined as the least saline hydration volume at which no more than 1 of 6
patients experience DLT.
PROJECTED ACCRUAL: Approximately 35 patients will be accrued into this study.
;
N/A
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|